Female patients must agree to the use of 2 methods of contraception. For man one method of contraception is needed if if his partner is in childbearing age throughout the study and for at least 5 months after last study treatment administration.
Patients with metastatic stage III or IV melanoma relapse
Eligible for a melanoma metastatic treatment indicated and administered as part of usual care
Patients must be willing and able to undergo cutaneous tumor biopsies (except on the face and folds or lymph node) according to the study protocol
Patient insured or beneficiary of a health insurance plan
Patient able to provide informed consent and sign approved consent forms to participate in the study
Patient accepting the conservation of biological samples and their use for clinical research including genetic research
You may not be if
Hematologic tumours under treatment
Patients with a documented history of autoimmune pathology
Ocular melanoma
Persons placed under the safeguard of justice
Use of immunosuppressants including corticosteroids 4 weeks before the inclusion
Clareo Health | Variations of Immune Infiltrate and Cell Plasticity Markers in Treated Metastatic Melanoma Patients
